Session: SUN 199-233-Bone Biology
Poster Board SUN-222
Design and Setting:This multi-arm parallel randomized controlled trial was performed at the Endocrine Department of the Academic Medical Center of the University of Amsterdam in The Netherlands from 2010 until 2012.
Subjects:32 healthy postmenopausal women who had their last menstrual cycle 12 to 60 months ago were recruited from the general population. Exclusion criteria were contraindications to the study treatment and diseases or medications influencing bone metabolism.
Intervention: Participants (n=8 per group) were randomized to receive treatment with 1] 17-beta estradiol (E2) 2 mg qd, 2] E2 2 mg qd and terbutaline 5 mg qd, 3] propranolol SR 80 mg qd or 4] no treatment during 12 weeks.
Outcome measure:The main outcome measure was the difference in serum concentrations of the bone resorption marker C-terminal crosslinking telopeptides of collagen type I (CTx) and the bone formation marker procollagen type I N propeptide (P1NP) compared in the treatment and control groups after 12 weeks.
Results: CTx and P1NP at baseline were not different between groups. CTx and P1NP were lower during 12 weeks of E2 compared to control (mean difference at 12 weeks: CTx 175 ng/L or 54% change (p=0.008), P1NP 21 ug/L or 33% change (p=0.000)). For CTx the maximal effect was already observed after four weeks of treatment. Addition of beta-agonist to estrogen or beta-antagonist treatment had no effect on CTx and P1NP concentrations.
Conclusion: Estrogen treatment decreased bone turnover as expected already within 4 weeks. Beta-antagonist treatment and addition of beta-agonist treatment to estrogen had no effect on bone turnover. Therefore we could not confirm the effect of pharmacological beta-adrenergic stimulation or inhibition on human bone remodeling.
Trial registration number: Netherlands Trial Registry TC 2874
Funding: This work was supported by The Netherlands Organization for Health Research and Development (ZonMw) Ref: 90700308.
Disclosure: The authors have nothing to disclose.
Nothing to Disclose: AGV, EE, ACH, MWT, PL, BLV, EF, PHB
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters